Compare FNLC & MASS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNLC | MASS |
|---|---|---|
| Founded | 1864 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.7M | 326.0M |
| IPO Year | 1995 | 2020 |
| Metric | FNLC | MASS |
|---|---|---|
| Price | $35.31 | $7.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 31.5K | ★ 224.7K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.19% | N/A |
| EPS Growth | 26.34 | ★ 125.47 |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | ★ $56,197,000.00 |
| Revenue This Year | N/A | $19.44 |
| Revenue Next Year | N/A | $18.63 |
| P/E Ratio | $43.61 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.13 | $5.03 |
| 52 Week High | $35.93 | $9.34 |
| Indicator | FNLC | MASS |
|---|---|---|
| Relative Strength Index (RSI) | 63.38 | 35.08 |
| Support Level | $28.08 | $6.48 |
| Resistance Level | $35.93 | $7.45 |
| Average True Range (ATR) | 1.24 | 0.44 |
| MACD | -0.07 | -0.09 |
| Stochastic Oscillator | 82.84 | 10.06 |
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services, including deposit accounts and consumer, commercial, and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.